Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
Thrombosis Journal
Published in: Thrombosis Journal 1/2003

Open Access 01-12-2003 | Review

Point-of-Care Testing of Hemostasis in Cardiac Surgery

Authors: Domenico Prisco, Rita Paniccia

Published in: Thrombosis Journal | Issue 1/2003

Login to get access

Abstract

An excessive perioperative blood loss, that requires transfusion of blood products, sometimes occurs in patients undergoing cardiopulmonary bypass for cardiac surgery. Blood loss and transfusion requirements in these patients may be reduced with a better control of heparin treatment and its reversal. Blood component administration in patients with excessive post-cardiopulmonary bypass bleeding has been empiric for a long time due to turnaround times of laboratory coagulation tests. Devices are now available for rapid, point-of-care assessment of hemostasis alterations to allow an appropriate, targeted therapy. In particular, a quick evaluation of platelet and coagulation defects with new point-of-care devices can optimize the administration of pharmacological and transfusion-based therapy in patients with excessive bleeding after cardiopulmonary bypass.
Literature
1.
Hattersley P: Activated coagulation time of whole blood. JAMA 1966, 136: 436-439.CrossRef
2.
Lee RI, White PD: A clinical study of the coagulation time of blood. Am J Med Sci 1913, 145: 495-503.CrossRef
3.
Bull BS, Huse WM, Brauer FS, Korpman RA: Heparin therapy during extracorporeal circulation. II. The use of a dose-response curve to individualize heparin and protamine dosage. J Thorac Cardiovasc Surg 1975, 69: 685-689.PubMed
4.
Despotis GJ, Gravlee G, Filos K, Levy J: Anticoagulation monitoring during cardiac surgery: a review of current and emerging techniques. Anesthesiology 1999, 91: 1122-1151.CrossRefPubMed
5.
Despotis GJ, Joist JH: Anticoagulation and anticoagulation reversal with cardiac surgery involving cardiopulmonary bypass: an update. J Cardiothorac Vasc Anesth 1999, 4: 18-29.
6.
Gravlee GP, Case LD, Angert KC, Rogers AT, Miller GS: Variability of the activated coagulation time. Anesth Analg 1988, 67: 469-472.PubMed
7.
Carter AJ, Hicks K, Heldman AW, Resar JR, Laird JR, Coombs VJ, Brinker JA, Blumenthal RS: Clinical evaluation of a microsample coagulation analyzer, and comparison with existing techniques. Cathet Cardiovasc Diagn 1996, 39: 97-102.CrossRefPubMed
8.
Schneuwly OD, Reber G, Licker M, de Moerloose P: Celite ACT measurement: comparison of I-STAT ® . A new assay system, with conventional Hemochron ® . [abstract]. Thromb Haemostas 2001, Supplement July 2001: P679.
9.
Paniccia R, Fedi S, Carbonetto F, Noferi D, Conti P, Bandinelli B, Giusti B, Evangelisti L, Pretelli P, Palmarini MFG, Abbate R, Prisco D: Evaluation of a New Point-Of-Care Celite Activated Clotting Time (ACT) Analyzer in Different Clinical Settings: the i-STAT Celite ACT Test. Anesthesiology 2003, in press.
10.
Bland JM, Altman DG: Statistical methods for assessing agreement between two methods of clinical measurements. Lancet 1986, 1: 307-310.CrossRefPubMed
11.
Bland JM, Altman DG: Comparing methods of measurements: why plotting difference against standard method is misleading. Lancet 1995, 346: 1085-1087.CrossRefPubMed
12.
Fitch JCK, Geary KLB, Mirto GP, Byrne DW, Hines RL: Heparin Management Test versus activated coagulation time during cardiovascular surgery: correlation with anti-Xa activity. J Cardiothorac Vasc Anesth 1999, 13: 53-57.CrossRefPubMed
13.
Welsby IJ, McDonnell E, El-Moalem H, Stafford-Smith M, Toffaletti JG: Activated clotting time systems vary in precision and bias and are not interchangeable when following heparin management protocols during cardiopulmonary bypass. J Clin Monit Comput 2002, 17: 287-292.CrossRefPubMed
14.
Forestier F, Belisle S, Contant C, Harel F, Janvier G, Hardy JF: Reproductibilité et interchangeabilité du Thromboélastographe, Sonoclot et du temps de coagulation activé (Hémochron), en chirurgie cardiaque. [Reproducibility and interchangeability of the Thromboelastograph, Sonoclot and Hemochron activated coagulation time in cardiac surgery]. Can J Anaesth 2001, 48: 902-910.CrossRefPubMed
15.
Andrew M, MacIntyre B, MacMillan J, Williams WG, Gruenwald C, Johnston M, Burrows F, Wang E, Adams M: Heparin therapy during cardiopulmonary bypass in children requires ongoing quality control. Thromb Haemostas 1993, 70: 937-941.
16.
Leyvi G, Shore-Lesserson L, Harrington D, Vela-Cantos F, Hossain S: An investigation of a new activated clotting time "MAX-ACT" in patient undergoing extracorporeal circulation. Anesth Analg 2001, 92: 578-583.CrossRefPubMed
17.
Zucker ML, Jobes C, Siegel M, Jobes D, LaDuca FM: Activated clotting time (ACT) testing: analysis of reproducibility. J Extra Corpor Technol 1999, 31: 130-134.PubMed
18.
Pan CM, Jobes D, Van Riper D, Ogilby JD, Lin CY, Horrow , Blumenthal R, Mendoza M, LaDuca F: Modified microsample ACT test for heparin monitoring. J Extracorpor Technol 1996, 28: 16-20.
19.
Despotis GJ, Summerfield AL, Joist JH, Goodnough LT, Santoro SA, Spitznagel E, Cox JL, Lappas DG: Comparison of activated coagulation time and whole blood heparin measurements with laboratory plasma anti-Xa heparin concentration in patients having cardiac operations. J Thorac Cardiovasc Surg 1994, 108: 1076-1082.PubMed
20.
Despotis GJ, Santoro SA, Spitznagel E, Kater KM, Cox JL, Barnes P, Lappas DG: Prospective evaluation and clinical utility of on-site monitoring of coagulation in patients undergoing cardiac operation. J Thorac Cardiovasc Surg 1994, 107: 271-279.PubMed
21.
Wachtfogel YT, Kucich U, Greenplate J, Gluszko P, Abrams W, Weibaum G, Wenger RK, Rucinski B, Niewiaroski S, Edmunds LH, et al.: Human neutrophil degranulation during extracorporeal circulation. Blood 1987, 69: 324-330.PubMed
22.
Khuri SF, Valeri CR, Loscalzo J, Weinstein MJ, Birjiniuk V, Healy NA, MacGregor H, Doursounian M, Zalkewitz MA: Heparin causes platelet dysfunction and induces fibrinolysis before cardiopulmonary bypass. Ann Thorac Surg 1995, 60: 1008-1014.CrossRefPubMed
23.
Cobel-Gerard RJ, Hassouna HI: Interaction of protamine sulfate with thombin. Am J Hematol 1983, 14: 227-233.CrossRef
24.
Holloway DS, Summaria L, Sandesara J, Vagher JP, Alexander HC, Caprini JA: Decreased platelet number and function and increased fibrinolysis contribute to postoperative bleeding in cardiopulmonary bypass patients. Thromb Haemostas 1988, 59: 62-67.
25.
Kalter RD, Saul CM, Wetstein L, Soriano C, Reiss RF: Cardiopulmonary bypass. Associated hemostatic abnormalities. J Thorac Cardiovasc Surg 1979, 77: 427-460.PubMed
26.
Slaughter TF, LeBleu TH, Douglas JM Jr, Leslie JB, Parker JK, Greenberg CS: Characterization of prothrombin activation during cardiac surgery by hemostatic molecular markers. Anesthesiology 1994, 80: 520-526.CrossRefPubMed
27.
Yoshihara H, Yamamoto T, Mihara H: Changes in coagulation and fibrinolysis occurring in dogs during hypothermia. Thromb Res 1985, 37: 505-512.
28.
Valeri CR, Feingold H, Cassidy G, Ragno G, Khuri S, Altschule MD: Hypothermia-induced reversible platelet dysfunction. Ann Surg 1987, 204: 175-181.CrossRef
29.
Despotis GJ, Joist JH, Goodnough LT: Monitoring of hemostasis in cardiac surgical patients: impact of point-of-care testing on blood loss and transfusion outcomes. Clin Chem 1997, 43: 1684-1696.PubMed
30.
Wang JS, Lin CY, Hung WT, Karp RB: Monitoring of heparin induced anticoagulation with kaolin-activated clotting time in cardiac surgical patients treated with aprotinin. Anesthesiology 1992, 77: 1080-1084.CrossRefPubMed
31.
32.
Khuri SF, Wolfe JA, Josa M, Axford TC, Szymanski I, Assousa S, Ragno G, Patel M, Silverman A, Park M, et al.: Hematologic chnges during and after cardiopulmonary bypass and their relationship to the bleeding time and non surgical blood loss. Thorac Cardiovasc Surg 1992, 104: 94-107.
33.
Greilich PE, Carr ME, Carr SL, Chang AS: Reductions in platelet force development by cardiopulmonary bypass are associate with hemorrhage. Anesth Analg 1995, 80: 459-465.PubMed
34.
Despotis GJ, Goodnough LT: Management approaches to platelet-related microvascular bleeding in cardiothoracic surgery. Ann Thorac Surg 2000, 70: S20-S32.CrossRefPubMed
35.
Jaryno S, Bennett K, Loder C, Zucker ML, Pan CM, LaDuca FM: Validation of a new whole blood coagulation monitoring system. J Extra Corpor Technol 2002, 34: 271-275.PubMed
36.
Giavarina D, Carta M, Fabbri A, Manfredi J, Gasparotto E, Soffiati G: Monitoring high-dose heparin levels by ACT and HMT during extracorporeal circulation: diagnostic accuracy of three compact monitors. Perfusion 2002, 17: 23-26.CrossRefPubMed
37.
Gravlee GP, Rogers AT, Dudas LM, Taylor R, Roy RC, Case LD, Triscott M, Brown CW, Mark LJ, Cordell AR: Heparin management protocol for cardiopulmonary bypass influences postoperative heparin rebound but not bleeding. Anesthesiology 1992, 76: 393-401.CrossRefPubMed
38.
Despotis GJ, Alsoufiev AL, Spitznagel E, Goodnough LT, Lappas DG: Response of kaolin ACT to heparin: evaluation with an automated assay and higher heparin doses. Ann Thorac Surg 1996, 61: 795-799.CrossRefPubMed
39.
Despotis GJ, Levine V, Joiner-Maier D, Joist JH: A comparison between continuous infusion versus standard bolus administration of heparin based on monitoring in cardiac surgery. Blood Coagul Fibrinolysis 1997, 8: 419-430.CrossRefPubMed
40.
Despotis GJ, Joist JH, Hogue CW Jr, Alsoufiev A, Kater K, Goodnough LT, Santoro SA, Spitznagel E, Rosenblum M, Lappas DG: The impact of heparin concentration and activated clotting time monitoring on blood conservation. A prospective, randomized evaluation in patients undergoing cardiac operation. Thorac Cardiovasc Surg 1995, 110: 46-54.CrossRef
41.
Koster A, Fischer T, Praus M, Haberzettl H, Kuebler WM, Hetzer R, Kuppe H: Hemostatic activation and inflammatory response during cardiopulmonary bypass: impact of heparin management. Anesthesiology 2002, 97: 837-841.CrossRefPubMed
42.
Gibbs NM, Weightman WM, Thackray NM, Michalopoulos N: Evaluation of the TAS coagulation analyzer for monitoring heparin effect in cardiac surgical patients. J Cardiothorac Vasc Anesth 1998, 12: 536-541.CrossRefPubMed
43.
Wallock M, Jeske WP, Bakhos M, Walenga JM: Evaluation of a new point of care heparin test for cardiopulmonary bypass: the TAS heparin management test. Perfusion 2001, 16: 147-151.CrossRefPubMed
44.
Slaughter TF, Grocott H, Greenblo K, Bennett-Guerrero E, Hilton A, Hodgins L, Mark JB: The Heparin management test (HMT™): an improved method for monitoring anticoagulation during cardiac surgery. Anesthesiology 1997, 85: A148.
45.
Muller-Plathe O, Ginzbourg J, Rudolph S: Evaluation of the i-STAT portable blood gas and electrolyte analyser. J Lab Med 1997, 21: 325-331.
46.
Ferring M, Reber G, de Moerloose P, Merlani P, Diby M, Ricou B: Point of care and central laboratory determinations of the aPTT are not interchangeable in surgical intensive care patients. Can J Anaesth 2001, 48: 1155-1160.CrossRefPubMed
47.
Boldt J, Walz G, Triem j, Suttner S, Kumble B: Point-of-care (POC) measurement of coagulation after cardiac surgery. Intensive Care Med 1998, 24: 1187-1193.CrossRefPubMed
48.
Salooja N, Perry DJ: Thromboelastography. Blood Coag Fibrinol 2001, 12: 327-337.CrossRef
49.
50.
Berkowitz SD, Frelinger AL III, Hillman RS: Progress in point-of-care laboratory testing for assessing platelet function. Am Heart J 1998, 136: S51-S65.CrossRefPubMed
51.
Shore-Lesserson L, Manspeizer HE, DePerio M, Francis S, Vela-Cantos F, Ergin MA: Thromboelastography-guided transfusion algorithm reduces transfusions in complex cardiac surgery. Anesth Analg 1999, 88: 312-319.PubMed
52.
Fries D, Innerhofer P, Klingler A, Berresheim U, Mittermayr M, Calatzis A, Schobersberger W: The effect of the combined administration of colloids and lactated Ringer's solution on the coagulation system: an in vitro study using thrombelastograph coagulation analysis (ROTEGR). Anesth Analg 2002, 94: 1280-1287.CrossRefPubMed
53.
Cammerer U, Dietrich W, Rampf T, Braun SL, Richter JA: The predictive value of modified computerized thromboelastography and platelet function analysis for postoperative blood loss in routine cardiac surgery. Anesth Analg 2003, 96: 51-57.PubMed
54.
Dong Y, Nuttall GA, Oliver WC, Ereth MH: Sonoclot analyzer and platelet aggregometry detect platelet receptor (GPIIb/IIIa) blockade. Anesthesiology 2001, 95: A192.CrossRef
55.
Nuttall GA, Oliver WC, Ereth MH, Santrach PJ: Coagulation tests predict bleeding after cardiopulmonary bypass. J Cardiothorac Vasc Anesth 1997, 11: 815-823.CrossRefPubMed
56.
Miyashita T, Kuro M: Evaluation of platelet function by Sonoclot analysis compared with other hemostatic variables in cardiac surgery. Anesth Analg 1998, 87: 1228-1233.PubMed
57.
Paniccia R, Ridolfi N, Stefano PL, Bandinelli B, Gazzini A, Evangelisti L, Ilari I, Marcucci R, Gensini GF, Prisco D: Two new "point of care" analyzers for the study of platelet function (PF) during cardiopulmonary bypass (CPB) [abstract]. Pathophysiol HemostasThromb 2002, 32: 111.
58.
Kundu SK, Heilmann EJ, Sio R, Garcia C, Davidson RM, Ostgaard RA: Description of an in vitro Platelet Function Analyzer-PFA-100™. Seminar Thromb Hemostas 1995, 21: 106-112.CrossRef
59.
Slaughter TF, Sreeram G, Sharma AD, E-Moalem H, East CJ, Greenberg CS: Reversible shear-mediated platelet dysfunction during cardiac surgery as assessed by the PFA-100Rplatelet function analyzer. Blood Coag Fibrinol 2001, 12: 85-93.CrossRef
60.
Lasne D, Fiemeyer A, Chatellier G, Chammas C, Baron JF, Aiach M: A study of platelet function with a new analyzer using high shear stress (PFA 100™) in patients undergoing coronary artery bypass graft. Thromb Haemost 2000, 84: 794-799.PubMed
61.
Despotis GJ, Levine V, Filos K, Santoro SA, Joist JH, Spitznagel E, Goodnough LT: Evaluation of a new point-of-care test that measures PAF-mediated acceleration of coagulation in cardiac surgical patients. Anesthesiology 1996, 85: 1311-1323.CrossRefPubMed
62.
Coiffic A, Cazes E, Janvier G, Forestier F, Lanza F, Nurden A, Nurden P: Inhibition of platelet aggregation by Abicixmab but not by Aspirin can be detected by a new point-of-care test, the Hemostatus. Thromb Res 1999, 95: 83-91.CrossRefPubMed
63.
Ereth MH, Nuttall GA, Klindworth JA, MacVeigh IM, Santrach PJ, Orszulak TA, Scott Harmsen W, Oliver Jr WC: Does the platelet-activated clotting test (HemostatusR) predict blood loss and platelet dysfunction associated with cardiopulmonary bypass? Anesth Analg 1997, 85: 259-264.PubMed
64.
Ereth MH, Nuttall GA, Santrach PJ, Klindworth JA, Oliver Jr WC, Schaff HV: The relation between the platelet-activated clotting test (Hemostatus) and blood loss after cardiopulmonary bypass. Anesthesiology 1998, 88: 962-969.CrossRefPubMed
65.
Shore-Lesserson L, Ammar T, DePerio M, Vela-Cantos , Fisher C, Sarier K: Platelet-activated clotting time does not measure platelet reactivity during cardiac surgery. Anesthesiology 1999, 91: 362-368.CrossRefPubMed
Metadata
Title
Point-of-Care Testing of Hemostasis in Cardiac Surgery
Authors
Domenico Prisco
Rita Paniccia
Publication date
01-12-2003
Publisher
BioMed Central
Published in
Thrombosis Journal / Issue 1/2003
Electronic ISSN: 1477-9560
DOI
https://doi.org/10.1186/1477-9560-1-1

Other articles of this Issue 1/2003

Thrombosis Journal 1/2003 Go to the issue

Review

Acute coronary disease Athero-Inflammation: Therapeutic approach

Original basic research

Induction of Tissue Factor Expression in Endothelial Cells by Basic Fibroblast Growth Factor and its Modulation by Fenofibric acid

Review

Risk factors in coronary atherosclerosis athero-inflammation: the meeting point

Original basic research

Multivariate relationships between international normalized ratio and vitamin K-dependent coagulation-derived parameters in normal healthy donors and oral anticoagulant therapy patients

Original clinical investigation

Angiotensin Converting Enzyme and Angiotensin II Type 1 Receptor Polymorphisms in Patients with Coronary Aneurysms

Original clinical investigation

Thrombin generation during cardiopulmonary bypass: the possible role of retransfusion of blood aspirated from the surgical field
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Reserve your place

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

Read more

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine
Image Credits